Xennials Therapeutics Australia Pty Ltd
Xennials Therapeutics Inc. is dedicated to developing transformative therapies and platforms that improve outcomes for cancer patients globally. They focus on innovative delivery technologies and novel assets to increase efficacy, patient compliance, and reduce side effects and costs. Their mission is to address unmet needs in cancer treatment through targeted, precise delivery of therapeutics, leveraging nanotechnology and proprietary platforms.
Industries
Nr. of Employees
small (1-50)
Xennials Therapeutics Australia Pty Ltd
John Hancock Tower, 875 N. Michigan Ave., Suite 3100, Chicago, IL 60611, United States
Products
Orally bioavailable DNMT1 inhibitor (clinical candidate for advanced solid tumors)
An orally administered small-molecule inhibitor of DNA methyltransferase 1 developed as a clinical-stage antineoplastic agent, evaluated as monotherapy and in combination with standard chemotherapies in Phase 1/2 studies.
Targeted multi-inhibitor therapeutic constructs (preclinical pipeline assets)
A set of construct candidates combining inhibitors (for example STAT inhibitors, androgen receptor N-terminal domain inhibitors, PARP inhibitors, EGFR-targeting moieties, and immune checkpoint inhibitor constructs) with targeting components or nanoparticle carriers to achieve multi-modal inhibition and targeted delivery.
Orally bioavailable DNMT1 inhibitor (clinical candidate for advanced solid tumors)
An orally administered small-molecule inhibitor of DNA methyltransferase 1 developed as a clinical-stage antineoplastic agent, evaluated as monotherapy and in combination with standard chemotherapies in Phase 1/2 studies.
Targeted multi-inhibitor therapeutic constructs (preclinical pipeline assets)
A set of construct candidates combining inhibitors (for example STAT inhibitors, androgen receptor N-terminal domain inhibitors, PARP inhibitors, EGFR-targeting moieties, and immune checkpoint inhibitor constructs) with targeting components or nanoparticle carriers to achieve multi-modal inhibition and targeted delivery.
Services
Sponsorship and operational execution of Phase 1/2 oncology trials including protocol development, ethics submissions, site coordination, and safety/efficacy evaluation.
Partnership-based co-development of oncology candidates and delivery platforms with external biotech organizations to advance preclinical and clinical programs.
Sponsorship and operational execution of Phase 1/2 oncology trials including protocol development, ethics submissions, site coordination, and safety/efficacy evaluation.
Partnership-based co-development of oncology candidates and delivery platforms with external biotech organizations to advance preclinical and clinical programs.
Expertise Areas
- Clinical trial management
- Oncology drug development
- Targeted drug delivery
- Nanoparticle therapeutics
Key Technologies
- Nanoparticle formulation and surface functionalization
- Targeted ligand conjugation for cell-specific delivery
- Orally bioavailable DNMT1 inhibition (small-molecule inhibitors)
- Multi-target inhibitory construct design
News & Updates
Update on the Phase 1/2 study of NTX-301, a DNMT1 inhibitor, including progress and ethical approvals.
Announcement of the enrollment of the first patient in the Phase 1/2 study of NTX-301 in advanced cancers.
Announcement of the initiation of a new clinical trial for NTX-301 in collaboration with PinotBio.
Discussion on nanotechnology applications in cancer therapy, including drug delivery and therapeutics.
Update on the Phase 1/2 study of NTX-301, a DNMT1 inhibitor, including progress and ethical approvals.
Announcement of the enrollment of the first patient in the Phase 1/2 study of NTX-301 in advanced cancers.
Announcement of the initiation of a new clinical trial for NTX-301 in collaboration with PinotBio.
Discussion on nanotechnology applications in cancer therapy, including drug delivery and therapeutics.